On December 14-16, 2018, sponsored by the Institute of Oncology of China Academy of Chinese Medical Sciences, co-organized by the Professional Committee of Chinese Medicine Oncology Drugs and Clinical Research of Chinese Pharmaceutical Association, and jointly participated by core experts from the Institute of Oncology of China Academy of Chinese Medical Sciences, the Center for Integrative Medicine of UT MD Anderson Cancer Center and the Center for Integrative Medicine of Memorial Sloan Katherine Cancer Center (MSKCC) in the United States. The International Symposium on TCM Oncology Drug Research and Efficacy Evaluation was held in Beijing, and the theme of the conference was "Multi-dimensional Integration, Innovative Development".

Yu Wenming, Director of the State Administration of Traditional Chinese Medicine, Wang Guoqiang, President of the China Association of Traditional Chinese Medicine, Sun Xianze, Chairman of the Chinese Pharmaceutical Association, and Huang Luqi, President of the China Academy of Chinese Medical Sciences, attended the meeting to congratulate and deliver speeches respectively. The leaders spoke highly of the convening of this conference as a milestone in scientifically leading the methods and strategies of TCM tumor drug research and efficacy evaluation, and promoting the establishment of a scientific evaluation system for TCM tumor efficacy. It is hoped that the experts and scholars attending the meeting will work together to use traditional Chinese medicine, the "key to open the treasure house of Chinese civilization", to open the mysterious door of tumor diseases as soon as possible and benefit all mankind.

During the conference, by sharing and discussing previous research results, drawing on reasonable and effective academic experience at home and abroad, the conference promoted the establishment of a consensus on the scientific evaluation of TCM tumor efficacy.

The meeting formed a preliminary consensus with the high concentration and enthusiastic participation of all experts, and everyone agreed that the combination of traditional Chinese medicine drugs and clinics, the combination of Chinese and foreign experts, the combination of government departments and groups, and the combination of enterprises and scholars will greatly promote the development of traditional Chinese medicine oncology drugs and clinics. The convening of this conference provides an important platform for further contacting experts in oncology-related fields at home and abroad, giving full play to the international promotion role of TCM oncology drug research, and promoting academic discussions and exchanges, which has made a big step forward in the research and efficacy evaluation of TCM oncology drugs.

Group photo of the participants 

The conference held the "International Symposium on Post-marketing Re-evaluation of Clinical Research" for Mengyang Pharmaceutical's flagship product "Shengbai Oral Liquid", and oncology experts from home and abroad conducted extensive discussions on the characteristics and clinical advantages of the product and gave high praise. In the future, Mengyang Pharmaceutical will continue to promote the development of TCM tumor clinical research, adhere to the path of scientific research and academic development, and devote itself to excavating the treasures of traditional medicine in the motherland for the benefit of mankind!

International Symposium on Post-Marketing Re-evaluation of Shengbai Oral Liquid